All News


All series


All All News

Losing my hair, eyebrows and eyelashes didn't change who I was. It didn't change they people who loved me. Thanks to bright colors and make up, people told me all the time that I looked great.

Join us on Tuesday, April 10 at 1 p.m. EST for our monthly #CureConnect tweet chat, where we’ll focus on our recent gastrointestinal cancers special issue.

The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.